Akeso Biomedicalincis An Early Stage Company Focused On Developing New Solutions For The Treatment Of Bacterial Infectionsmicrobial Biofilmsand Chronic Woundsthe Company Is Developing Products To Treat These Conditions Using A New Class Of Compoundsknown As Fe3Cthat Have Broad Spectrum Activity Against A Wide Range Of Bacteriaand A Silk Biomaterial Technology Exclusively Licensed From Tufts University Akeso S Lead Fe3C Product Is A Feed Additive Designed To Prevent Food Poisoning By Campylobactera Bacteria That Causes More Cases Of Foodborne Illness In The Eu Than Salmonellaecoli And Listeria Combinedwith An Estimated 280 000 Cases In The Uk And 1 3 Million Cases In The Us Each Yearthe Economic Cost Of Treating Patients Infected With Campylobacter In The Uk Is Reported To Be $1 5 Billionand Over $5 6 Billion In The Us
No conferences found for this company.
| Company Name | Akeso Biomedical Inc |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
